Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis - Full Text View

Purpose

In this pilot study the pharmacokinetics and safety of the antiretroviral combination of co-formulated emtricitabine/tenofovir/efavirenz will be studied in HIV-positive patients with pulmonary tuberculosis (TB) who are concomitantly treated with a standard rifampin-containing tuberculostatic regimen. It is expected that this antiretroviral combination causes minimal drug interactions with the rifampin-containing anti-tuberculosis medication.

Condition	Intervention	Phase
Tuberculosis HIV Infections	Drug: Emtricitabine/tenofovir/efavirenz	Phase 2

Study Type:	Interventional
Study Design:	Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS Tuberculosis

Drug Information available for: Emtricitabine Tenofovir Efavirenz Tenofovir Disoproxil Fumarate

U.S. FDA Resources

Further study details as provided by African Poverty Related Infection Oriented Research Initiative:

Primary Outcome Measures:

Pharmacokinetic parameters of emtricitabine, tenofovir and efavirenz [ Time Frame: Two 24 hour pharmacokinetic (PK) curves (week 8 and 28) ] [ Designated as safety issue: No ]
Pharmacokinetic parameters of the tuberculostatic agents [ Time Frame: Pharmacokinetic (PK) samples at 2 hours and 6 hours postdose (week 2 and 8) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Biochemistry and haematology samples for safety [ Time Frame: Samples at screening, baseline, week 2, 4, 6, 8, 12, 16, 24, 28 ] [ Designated as safety issue: Yes ]
Questioning about occurrence of adverse events [ Time Frame: At baseline, week 2, 4, 6, 8, 12, 16, 24, 28 ] [ Designated as safety issue: Yes ]
CD4 count and HIV-1 RNA [ Time Frame: At screening, week 4, week 16 and week 28 ] [ Designated as safety issue: Yes ]
Sputum staining and culture [ Time Frame: At screening, week 4, 8, and 28 ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	30
Study Start Date:	November 2008
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Intervention Details:

Co-formulated in one tablet (taken once daily by oral administration):

emtricitabine 200 mg
tenofovir DF 300 mg
efavirenz 600 mg

Detailed Description:

The primary objectives of this pilot study in 30 patients are:

To determine the effect of rifampin-containing tuberculostatic treatment on the pharmacokinetic profile of emtricitabine+tenofovir+efavirenz, when co-formulated in one tablet, in HIV-infected patients with smear-positive pulmonary tuberculosis in Tanzania.
To determine the effect of the emtricitabine+tenofovir+efavirenz regimen on the pharmacokinetics of tuberculostatics in the same population.

The secondary objectives are:

To determine the safety of co-administration of emtricitabine+tenofovir+efavirenz with treatment for smear-positive pulmonary tuberculosis.
To determine the short-term (24 weeks) virological efficacy on HIV of an emtricitabine+tenofovir+efavirenz regimen in patients with smear-positive pulmonary tuberculosis.
To determine the short-term bacteriological efficacy on smear-positive tuberculosis of the co-administration of a standard regimen for tuberculosis and an emtricitabine+tenofovir+efavirenz regimen.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

A smear-positive pulmonary tuberculosis, based on positive smear of at least two sputum samples with Ziehl-Neelsen (ZN) staining.
HIV-infected as documented by positive HIV antibody test.
Subject is at least 18 years of age at the day of the first dosing of study medication.
Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
CD4 cell count > 50 copies/mm3.
Karnofsky score > 40.
Willing and able to regularly attend the Kibung'oto National Tuberculosis Hospital (KNTH) clinic.

Exclusion Criteria:

History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients, which may be employed in the trial.
Previously treated for HIV infection with antiretroviral agents.
Pregnant or breastfeeding.
Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
A history of severe psychiatric disease such as psychosis, schizophrenia, etc.
Inability to understand the nature and extent of the trial and the procedures required.
Abnormal serum transaminases or creatinine, determined as levels being > 5 times upper limit of normal.
Active hepatobiliary or hepatic disease (Non B Chronic Hepatitis B/C co-infection is allowed).
CD4 cell count > 350 cells/mm3.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00474435

Contacts

Contact: Gibson Kibiki, MMed, PhD	+255 754 572767	gkibiki@gmail.com
Contact: Jossy van den Boogaard, MD	+255 787 148431	jossyvandenboogaard@gmail.com

Locations

Tanzania
Kibong'oto National Tuberculosis Hospital	Recruiting
Moshi, Kilimanjaro Region, Tanzania, P.O. Box 12
Contact: Liberate Mleoh, MD 027 2756194 lmleoh@yahoo.com
Principal Investigator: Gibson Kibiki, MMed, PhD
Sub-Investigator: Elton Kisanga, B-Pharm, PhD
Sub-Investigator: Liberate Mleoh, MD
Sub-Investigator: Jossy van den Boogaard, MD
Sub-Investigator: Hadija Semvua, B-Pharm, MPH
Sub-Investigator: Charles Mtabho, MD, MPH

Sponsors and Collaborators

African Poverty Related Infection Oriented Research Initiative

Radboud University

Kilimanjaro Christian Medical Centre, Tanzania

Investigators

Principal Investigator:	Martin Boeree, MD, PhD	University Lungcentre Dekkerswald, Groesbeek / University Medical Centre Nijmegen, the Netherlands
Principal Investigator:	David Burger, PharmD, PhD	University Medical Centre Nijmegen, the Netherlands
Principal Investigator:	Gibson Kibiki, MMed, PhD	Kilimanjaro Christian Medical Centre, Moshi, Tanzania

More Information

Publications:

Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet. 2000 Oct 28;356(9240):1488-9.

Msamanga GI, Fawzi WW. The double burden of HIV infection and tuberculosis in sub-Saharan Africa. N Engl J Med. 1997 Sep 18;337(12):849-51. No abstract available.

Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002 Jan 4;16(1):75-83.

Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327-41. Review.

Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002 May 13;162(9):985-92. Review.

Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681-90.

Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 Jul;37(7):1426-31.

Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC, Cameron DW. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999 Aug;48(2):168-79.

Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N, El Sadr W. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S421-8.

Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):287-91.

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001 Jan 5;15(1):71-5.

Responsible Party:	Martin Boeree, University Lungcentre Dekkerswald, Groesbeek, the Netherlands
ClinicalTrials.gov Identifier:	NCT00474435 History of Changes
Other Study ID Numbers:	UMCN-AKF 04.03
Study First Received:	May 16, 2007
Last Updated:	December 16, 2010
Health Authority:	Tanzania: Food & Drug Administration

Keywords provided by African Poverty Related Infection Oriented Research Initiative:

Tuberculosis
HIV
Coinfection
Pharmacokinetics
Emtricitabine

Tenofovir
Rifampin
Efavirenz
Treatment Naive

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Tuberculosis
Tuberculosis, Pulmonary
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Mycobacterium Infections
Actinomycetales Infections

Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Tenofovir
Tenofovir disoproxil
Efavirenz
Emtricitabine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents

ClinicalTrials.gov processed this record on June 18, 2013

Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis (PETE)